Literature DB >> 20154243

Helping patients with localized prostate cancer reach treatment decisions.

Kathryn Birnie1, John Robinson.   

Abstract

OBJECTIVE: To highlight the role of psychosocial variables in treatment decision making for patients with localized prostate cancer and how family physicians can be of most help to such patients in facilitating good treatment choices. QUALITY OF EVIDENCE: PubMed was searched, and articles relevant to the psychosocial aspects of localized prostate cancer treatment decision making were included. Articles were excluded when they clearly specified inclusion of men with metastatic disease. This is not a systematic review, and recommendations made are drawn from studies of level II or III evidence. MAIN MESSAGE: The optimal strategy for managing localized prostate cancer has not been established and currently includes a number of potential options: active surveillance, radical prostatectomy, external beam radiotherapy, brachytherapy, and cryoablation. Consequently, men often struggle during the decision-making process, and some later regret their decisions. With an increased awareness of the psychosocial aspects of patient decision making, family physicians can help patients make better decisions.
CONCLUSION: Family physicians can help minimize the decisional regret experienced by patients after treatment by encouraging patients to consider their values and social supports, as well as the accuracy and appropriateness of the information used in the decision-making process.

Entities:  

Mesh:

Year:  2010        PMID: 20154243      PMCID: PMC2821233     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  34 in total

1.  Decision-making strategies for patients with localized prostate cancer.

Authors:  Michael A Diefenbach; Jenevie Dorsey; Robert G Uzzo; Gerald E Hanks; Richard E Greenberg; Eric Horwitz; Fredrick Newton; Paul F Engstrom
Journal:  Semin Urol Oncol       Date:  2002-02

2.  The information required by patients with early-stage prostate cancer in choosing their treatment.

Authors:  D Feldman-Stewart; M D Brundage; J C Nickel; W J MacKillop
Journal:  BJU Int       Date:  2001-02       Impact factor: 5.588

3.  Making decisions about treatment for localized prostate cancer.

Authors:  S K Steginga; S Occhipinti; R A Gardiner; J Yaxley; P Heathcote
Journal:  BJU Int       Date:  2002-02       Impact factor: 5.588

4.  Decisional regret and quality of life after participating in medical decision-making for early-stage prostate cancer.

Authors:  B J Davison; S L Goldenberg
Journal:  BJU Int       Date:  2003-01       Impact factor: 5.588

5.  Is 'watchful waiting' a real choice for men with prostate cancer? A qualitative study.

Authors:  A Chapple; S Ziebland; A Herxheimer; A McPherson; S Shepperd; R Miller
Journal:  BJU Int       Date:  2002-08       Impact factor: 5.588

6.  Regret in men treated for localized prostate cancer.

Authors:  Jim C Hu; Lorna Kwan; Christopher S Saigal; Mark S Litwin
Journal:  J Urol       Date:  2003-06       Impact factor: 7.450

7.  Partner's influence on patient preference for treatment in early prostate cancer.

Authors:  S J Srirangam; E Pearson; C Grose; S C W Brown; G N Collins; P H O'Reilly
Journal:  BJU Int       Date:  2003-09       Impact factor: 5.588

8.  Patients' preferences for communicating a prostate cancer diagnosis and participating in medical decision-making.

Authors:  B J Davison; P A Parker; S L Goldenberg
Journal:  BJU Int       Date:  2004-01       Impact factor: 5.588

9.  Provision of individualized information to men and their partners to facilitate treatment decision making in prostate cancer.

Authors:  B Joyce Davison; S Larry Goldenberg; Martin E Gleave; Lesley F Degner
Journal:  Oncol Nurs Forum       Date:  2003 Jan-Feb       Impact factor: 2.172

10.  Who decides about prostate cancer treatment? A qualitative study.

Authors:  Howard Cohen; Nicky Britten
Journal:  Fam Pract       Date:  2003-12       Impact factor: 2.267

View more
  7 in total

1.  First do no harm?

Authors:  Bart J Harvey; Anthony B Miller
Journal:  Can Fam Physician       Date:  2010-05       Impact factor: 3.275

2.  Cancer patients' and clinicians' opinions on the best time in secondary care to approach patients for recruitment to longitudinal questionnaire-based research.

Authors:  Laura Ashley; Helen Jones; Galina Velikova; Penny Wright
Journal:  Support Care Cancer       Date:  2012-06-22       Impact factor: 3.603

3.  The provision of prostate cancer patient information leaflets on an electronic tablet: A further step to paperless health-care provision.

Authors:  Saiful Miah; Jonathon Maw; Karl Pang; Vineetha Nair; Satoshi Hori; Alastair Lamb; Alexander Martin; Ola Bratt; Benjamin Lamb; Nimish Shah
Journal:  Urol Ann       Date:  2022-02-15

4.  Decision-making by surgeons about referral for adjuvant therapy for patients with non-small-cell lung, breast or colorectal cancer: a qualitative study.

Authors:  Robin Urquhart; Cynthia Kendell; Gordon Buduhan; Daniel Rayson; Joan Sargeant; Paul Johnson; Eva Grunfeld; Geoffrey A Porter
Journal:  CMAJ Open       Date:  2016-01-12

Review 5.  A synthesis of clinical recommendations and primary research for survivors of prostate or breast cancer.

Authors:  Melanie Sandoval; Jennifer Wenzel; Randy Jones
Journal:  Clin J Oncol Nurs       Date:  2014-12       Impact factor: 1.027

6.  Healthcare practices that increase the quality of care in cancer trajectories from a general practice perspective: a scoping review.

Authors:  Anne Nicolaisen; Gitte Bruun Lauridsen; Peter Haastrup; Dorte Gilså Hansen; Dorte Ejg Jarbøl
Journal:  Scand J Prim Health Care       Date:  2022-03-07       Impact factor: 3.147

7.  How do surgeons decide to refer patients for adjuvant cancer treatment? Protocol for a qualitative study.

Authors:  Robin Urquhart; Cynthia Kendell; Joan Sargeant; Gordon Buduhan; Paul Johnson; Daniel Rayson; Eva Grunfeld; Geoffrey A Porter
Journal:  Implement Sci       Date:  2012-10-25       Impact factor: 7.327

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.